Extensive research has highlighted the role of TRIM proteins in antiviral responses against hepatitis B. In particular, TRIM19, TRIM38, and TRIM25 have been implicated in HBsAg clearance and improved therapeutic outcomes following peg-IFN-α treatment (106, 107). The gene discussed is IFNA2; the disease is hepatitis B virus infection.